Help us: Donate
Follow us on:
×

Menu

Back

Tag: UNITY Biotechnology

Scientific Announcement
Leading the pack is never easy, but today, UNITY Biotechnology is back with some positive news for senolytics. Being first is not always easy UNITY Biotechnology is a company that has been developing senolytics for the removal of senescent cells, which accumulate with age, drive chronic inflammation, and spur various age-related diseases. Why we Age:...
Longevity Therapeutics banner
Like nearly all conferences this past year, the 3rd Annual Longevity Therapeutics Summit, presented by Hanson Wade Limited, went virtual this time around. This was a stark difference from the previous two, which were rather fancy affairs in downtown San Francisco. However, we were fortunate that the organizers went forward with the event, bringing together...
Dr. Judith Campisi
At Ending Age-Related Diseases 2020, Prof. Judith Campisi of the Buck Institute for Research on Aging discussed the effects and usage of senolytics, drugs that remove senescent cells from the body. She went into the details of the stress and damage signals that cause cells to become senescent and the markers of senescent cells, noting...
Rejuvenation Roundup October
Spooky season has come and gone, but the Grim Reaper is still chasing us down. Fortunately, we've learned quite a bit over the last month in finding ways to stop Death from getting a hold of us quite so soon. LEAF News Based in the United Kingdom, the All Party Parliamentary Group (APPG) for Longevity...
Unity biotechnology logo
Unity Biotechnology has recently announced the launch of its Phase 1 study of UBX1325 for patients with diabetic macular edema. The drug is designed to remove problematic senescent cells from the body which accumulate as we get older and are a reason we age. Why we Age: Cellular SenescenceAs your body ages, more of your...
Unity biotechnology logo
While we enjoy reporting positive news, we do occasionally have to report bad news, and today is one of those days. There has been some disappointing news from UNITY Biotechnology with the release of its Phase 2 senolytic trial of its candidate drug UBX0101. SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY...